Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 17;28:438. doi: 10.1186/s40001-023-01383-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — The genetic alterations of RNF43. A Summary of RNF43 structural variant, mutations, and copy-number alterations. B Summary of RNF43 alterations in TCGA pan-cancer cohort. C The putative copy-number alterations of RNF43 in pan-cancer. D The mutation number, type, and site of the RNF43 genetic alterations. E The cooccurrence of gene alteration in RNF43 altered group and unaltered group. F Correlations of RNF43 alternations with PFS in TCGA pan-cancer cohort. G Correlations of RNF43 alternations with DSS in TCGA pan-cancer cohort. H Correlations of RNF43 alternations with OS in TCGA pan-cancer cohort. I Correlations of RNF43 alternations with mutation count in TCGA pan-cancer cohort. J Correlations of RNF43 alternations with TMB in TMB and immunotherapy cohort. K Correlations of RNF43 alternations with mutation count in TMB and immunotherapy cohort. L Correlations of RNF43 alternations with TMB in TMB and immunotherapy cohort